psoriasis/maumivu ya kichwa

Kiungo kimehifadhiwa kwenye clipboard

Chagua aina ya aina

Ukurasa 1 kutoka 151 matokeo

Low-dose Naltrexone Therapy for Psoriasis.

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

Safe, inexpensive, and convenient psoriasis therapy is desirable. Two recent case reports suggested that low-dose naltrexone is effective. Cases from our practice are presented in order to further the evidence of efficacy and safety of low-dose naltrexone in the treatment of psoriasis. Patients

Multiple sclerosis is associated with psoriasis. A case-control study.

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

BACKGROUND MS and psoriasis are both autoimmune diseases putatively mediated mainly by T cells. OBJECTIVE We conducted a case control study to investigate whether patients with MS have a high rate of comorbid psoriasis. METHODS The cohort consisted of 214 consecutive MS patients and a control group

Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study.

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

BACKGROUND No clinical trial of efalizumab has been conducted in Asia. OBJECTIVE To determine the efficacy and safety of efalizumab in Taiwanese patients with psoriasis. METHODS This is an open-label, single-arm pilot study conducted at two centres. Patients were given 1 mg/kg efalizumab

Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody.

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

Pathologic T-cell activation is implicated in psoriasis progression. CD80, a costimulatory molecule involved in T-cell activation, likely plays a key role. IDEC-114, an IgG(1) anti-CD80 antibody, was evaluated for safety, pharmacokinetics, and preliminary clinical activity in this open-label,

Efficacy and Safety of Apremilast in Patients With Moderate to Severe Plaque Psoriasis of the Scalp: Results of a Phase 3b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study.

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

Many psoriasis patients are bothered by symptoms in highly visible, pruritic areas, such as the scalp.Evaluate efficacy and safety of apremilast for moderate to severe scalp psoriasis.This phase 3b, double-blind,

Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis.

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

BACKGROUND CD11a/CD18 comprise subunits of leukocyte function associated antigen (LFA-1), a T-cell surface molecule important in T-cell activation, T-cell emigration into skin, and cytotoxic T-cell function. OBJECTIVE We explored the immunobiologic and clinical effects of treating moderate to severe

Efaluzimab in the treatment of psoriasis.

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

We present a review of the literature concerning treatment of psoriasis with humanized monoclonal antibody (hu 1124, efaluzimab, Xanelin) against the CD11a component of lymphocyte-function-associated antigen-1 (LFA-1). Efaluzimab inhibits the interaction of CD11a (LFA-1) with various ICAM molecules.

Parenteral interferon-alpha treatment of psoriasis.

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

12 patients suffering from psoriasis were given recombinant interferon (IFN)-alpha-2c at a daily dosage of 2.5 X 10(6) or 5 X 10(6) IU for up to 4 weeks by the intramuscular route. One patient showed complete regression and remained free of lesions after 12 months of follow-up. Three patients were

Generalized pustular psoriasis following withdrawal of efalizumab.

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

Efalizumab is one of the new biologic therapies targeting T-lymphocyte activity for the treatment of chronic plaque psoriasis. Common adverse effects include headaches, nonspecific infection, nausea, chills, and fever. Rebound of psoriasis following discontinuation of the drug has been reported.

Improvement of Nail and Scalp Psoriasis Using Apremilast in Patients With Chronic Psoriasis: Phase 2b and 3, 52-Week Randomized, Placebo-Controlled Trial Results.

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

BACKGROUND A significant portion of patients with psoriasis have scalp and nail involvement. It has been reported that 40% to 45% of patients with psoriasis have nail psoriasis, and up to 80% have scalp involvement. Nail and scalp psoriasis have often been found to be difficult to treat, due to the

Etanercept and efalizumab for the treatment of psoriasis: a systematic review.

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

OBJECTIVE To evaluate the clinical effectiveness, safety, tolerability and cost-effectiveness of etanercept and efalizumab for the treatment of moderate to severe chronic plaque psoriasis. METHODS Major electronic databases and several Internet resources were searched up to April

Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

BACKGROUND Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works intracellularly to modulate pro-inflammatory and anti-inflammatory mediator production. OBJECTIVE Assess apremilast efficacy and safety in moderate to severe plaque psoriasis. METHODS Phase II, 12-week,

A Comparative Evaluation of Modined Goeckerman Regimen and Oral Psoralens Plus Phototherapy in Psoriasis.

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

I Employing psoralen plus solar irradiation therapy in 20 patients with plaque psoriasis, improvement was noted in 55% of the patients. The overall improvement rate was however higher (95%) with coal tar plus solar irradiation treatment in the other group of 20 patients. In both groups, improvement

Comparison of trioxsalen bath and oral methoxsalen PUVA in psoriasis.

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

Fifty patients with chronic plaque psoriasis were treated with trioxsalen bath PUVA and 43 patients with oral methoxsalen PUVA. The two treatment regimens gave similar results; 75% and 77% of the patients had excellent or good clearing and a follow-up of one year revealed relapses in 61% and 58% of

Acupuncture as a Complementary Method of Traditional Psoriasis Treatment: Myth or Reality?

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

Dear Editor, the practitioners of traditional Chinese medicine described psoriasis some 2000 years ago (1). Psoriasis vulgaris is a common, chronic inflammatory skin disease whose worldwide prevalence ranges from 0.1-3% (2,3). Understanding the role of the immune system in psoriasis and the

Iliyotangulia
1
2
3
4
5
6
...
10
11
Ifuatayo

Jiunge na ukurasa
wetu wa facebook

Herbal & Natural Medicine

Hifadhidata kamili ya mimea ya dawa inayoungwa mkono na sayansi

Inafanya kazi katika lugha 55
Uponyaji wa mitishamba unaungwa mkono na sayansi
Kutambua mimea kwa picha
Ramani ya GPS inayoshirikiana
Soma machapisho ya kisayansi yanayohusiana na utafutaji wako
Tafuta mimea ya dawa na athari zao
Panga maslahi yako na fanya tarehe ya utafiti wa habari, majaribio ya kliniki na ruhusu

Andika dalili au ugonjwa na usome juu ya mimea ambayo inaweza kusaidia, chapa mimea na uone magonjwa na dalili ambazo hutumiwa dhidi yake.
* Habari zote zinategemea utafiti wa kisayansi uliochapishwa